查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612804

心臟 POC 測試市場：按產品類型、生物標記類型、最終用戶分類 - 2025-2030 年全球預測

Cardiac Point of Care Testing Market by Product (Analyzers, Kits & Assays, Software & Services), Biomarker Type (Cardiac Troponins, CK-MB Fraction, D-Dimer), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年心臟POC測試市場價值為83.1億美元，預計到2024年將達到93.8億美元，複合年成長率為13.14%，到2030年將達到197.4億美元。

心臟照護端測試 (POCT) 是指在患者照護端或附近進行的醫療診斷測試，以快速識別心臟病發作或心臟衰竭等心臟心臟疾病。對心臟 POCT 的需求源於心血管疾病快速診斷和治療的迫切需要，心血管疾病仍然是全球死亡的主要原因。心臟 POCT 的主要應用包括急診、加護病房和其他關鍵環境，在這些環境中快速獲得結果可以顯著改善患者的治療結果。最終用途包括醫院、診所、門診診所和居家醫療，反映了其在醫療保健服務中的多功能性和重要性。

主要市場統計
基準年[2023] 83.1億美元
預計年份 [2024] 93.8億美元
預測年份 [2030] 197.4億美元
複合年成長率（%） 13.14%

從市場角度來看，心血管疾病的日益普及和微型生物感測器等技術進步正在推動心臟 POCT 的成長。對快速檢測的需求不斷成長，尤其是在偏遠地區和資源有限的環境中，這使得快速檢測變得更加重要。然而，先進 POCT 設備的高成本、監管障礙以及與實驗室測試相比準確性不同等挑戰可能會阻礙市場成長。關鍵機會在於透過具有成本效益的解決方案和更高的準確性來擴大存取範圍，並有可能整合人工智慧和機器學習以改善預測分析。

儘管有這些挑戰，心臟 POCT 市場仍提供了重大的創新機會，特別是在開發可以從單一檢體提供全面面板測試的多項目 POCT 設備方面。促進技術開發人員和醫療保健提供者之間的協作可以創建更易於使用且更有效率的測試。公司可以透過關注醫療基礎設施有限但心臟疾病率高的地區並開發客製化解決方案來滿足未滿足的需求而受益。

綜上所述，心臟 POCT 市場雖然面臨成本和監管問題等限制，但透過解決技術改進和擴大應用領域提供了巨大的機會。透過策略創新和協作努力，我們可以利用這些機會，推動市場持續成長並改善患者照護。

市場動態：揭示快速發展的心臟 POC 測試市場的關鍵市場洞察

供需的動態交互作用正在改變心臟 POC 測試市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 患有心血管疾病的人口不斷增加
    • 政府對POC測試的優惠政策介紹
    • 改善世界各地的醫療保健支出
  • 市場限制因素
    • 心臟 POC 測試中使用的材料和組件的成本變化
  • 市場機會
    • 心臟 POC 測試的改進和持續進步
    • 開發新生物標記以提高檢測能力的進展
  • 市場挑戰
    • 心臟 POC 測試的操作和技術複雜性

波特五力：駕馭心臟 POC 測試市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解心臟 POC 測試市場的外部影響

外部宏觀環境因素在塑造心臟 POC 測試市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解心臟 POC 檢測市場的競爭狀況

心臟 POC 測試市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣心臟POC測試市場供應商績效評估

FPNV定位矩陣是評估心臟POC測試市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，規劃心臟 POC 測試市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對心臟 POC 測試市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人群心血管疾病發生率增加
      • 政府對POC測試的積極推動介紹
      • 改善世界各地經濟體的醫療保健支出
    • 抑制因素
      • 心臟 POC 測試中使用的材料和組件的成本變化
    • 機會
      • 心臟 POC 測試的改進和持續進步
      • 新生物標記物開發進展以提高檢測能力
    • 任務
      • 心臟 POC 測試的操作和技術複雜性
  • 市場區隔分析
    • 產品：診所對多重檢測的需求增加
    • 生物標記類型：用於早期心臟檢測的心臟型脂肪酸結合蛋白質（H-FABP）和缺血修飾白蛋白（IMA）的需求不斷增加
    • 最終用戶：在具有大樣本量的複雜系統的診斷實驗室中增加使用心臟 POC 測試
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章心臟 POC 測試市場：依產品

  • 分析儀
  • 套件和檢測
  • 軟體和服務

第7章按生物標記類型分類的心臟 POC 測試市場

  • 心肌肌鈣蛋白
  • CK-MB分數
  • D-二聚體
  • 心型脂肪酸結合蛋白質（H-FABP）
  • 同型半胱氨酸
  • hs C 反應蛋白 (CRP)
  • 缺血修飾白蛋白 (IMA)
  • 肌紅蛋白
  • 利尿鈉肽 (NP)
    • 心房鈉尿肽 (ANP)
    • B 型利尿鈉肽 (BNP)
    • N 端 BNP 前驅物 (NT-BNP 前驅物)
  • sCD40L

第 8 章 心臟 POC 測試市場：依最終用戶分類

  • 診斷實驗室
  • 醫院/診所
  • 研究/學術機構

第9章 北美和南美心臟POC測試市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太心臟POC測試市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲心臟POC測試市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Hipro照護現場診斷在印度推出
    • Jana Care 與羅氏合作開發和分銷血液檢測平台，以改善慢性腎臟病和心臟病患者的遠距護理
    • Cipla 擴大診斷產品組合併推出就地檢驗設備
  • 戰略分析和建議

公司名單

  • Abaxis, Inc. by Zoetis Inc
  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cardiac Insight Inc.
  • CardioGenics Holdings Inc.
  • Chembio Diagnostic Systems, Inc. by Biosynex
  • EKF Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio
  • Horiba, Ltd.
  • I-Sens Inc.
  • LifeSign LLC
  • Nexus Dx, Inc. by Sinocare
  • Nova Biomedical
  • PTS Diagnostics by Danaher Corporation
  • Quidel Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trividia Health, Inc.
Product Code: MRR-3F5063247F53

The Cardiac Point of Care Testing Market was valued at USD 8.31 billion in 2023, expected to reach USD 9.38 billion in 2024, and is projected to grow at a CAGR of 13.14%, to USD 19.74 billion by 2030.

Cardiac Point of Care Testing (POCT) refers to medical diagnostic testing performed at or near the site of patient care, aimed at swiftly identifying cardiac conditions like heart attacks or heart failure. The necessity for cardiac POCT stems from the urgent need for rapid diagnosis and treatment of cardiovascular diseases, which remain a leading cause of mortality globally. Its primary applications include emergency departments, intensive care units, and other critical scenarios where quick results can significantly improve patient outcomes. The end-use scope extends to hospitals, clinics, ambulatory care settings, and even home care, reflecting its versatility and importance in healthcare delivery.

KEY MARKET STATISTICS
Base Year [2023] USD 8.31 billion
Estimated Year [2024] USD 9.38 billion
Forecast Year [2030] USD 19.74 billion
CAGR (%) 13.14%

From a market perspective, the increasing prevalence of cardiovascular diseases, coupled with advancements in technology such as miniaturized biosensors, is driving the growth of cardiac POCT. Growing demand for rapid testing, especially in remote or resource-limited settings, further amplifies its significance. However, challenges like high costs of advanced POCT devices, regulatory hurdles, and variable accuracy compared to laboratory testing can impede market growth. A key opportunity lies in expanding access through cost-effective solutions and enhanced accuracy, potentially by integrating AI and machine learning for improved predictive analytics.

Despite these challenges, the cardiac POCT market offers significant innovation opportunities, particularly in the development of multi-analyte POCT devices capable of delivering comprehensive panel testing from a single sample. Encouraging collaborative efforts between technology developers and healthcare providers can foster the creation of more user-friendly and efficient tests. Businesses could benefit by focusing on geographic regions with limited healthcare infrastructure but high cardiac disease prevalence, creating tailored solutions to meet unmet needs.

In summary, while the cardiac POCT market faces limitations, such as cost and regulatory issues, it presents ripe opportunities by addressing technological improvements and expanding applications. Strategic innovation and collaboration efforts can harness these opportunities to drive sustained market growth and improved patient care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiac Point of Care Testing Market

The Cardiac Point of Care Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of cardiovascular disorders among the population
    • Favorable government initiatives for the introduction of POC testing
    • Improving healthcare expenditure across economies worldwide
  • Market Restraints
    • Fluctuating cost of materials and components used in cardiac POC testing
  • Market Opportunities
    • Improvements and continuous advancements in cardiac POC testing
    • Advances in the development of new biomarkers to improve testing capabilities
  • Market Challenges
    • Operational and technical complexities in cardiac POC testing

Porter's Five Forces: A Strategic Tool for Navigating the Cardiac Point of Care Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiac Point of Care Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiac Point of Care Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiac Point of Care Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiac Point of Care Testing Market

A detailed market share analysis in the Cardiac Point of Care Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiac Point of Care Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiac Point of Care Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiac Point of Care Testing Market

A strategic analysis of the Cardiac Point of Care Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Point of Care Testing Market, highlighting leading vendors and their innovative profiles. These include Abaxis, Inc. by Zoetis Inc, Abbott Laboratories, ACON Laboratories, Inc., Beckman Coulter, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardiac Insight Inc., CardioGenics Holdings Inc., Chembio Diagnostic Systems, Inc. by Biosynex, EKF Diagnostics, F. Hoffmann-La Roche Ltd., Fujirebio, Horiba, Ltd., I-Sens Inc., LifeSign LLC, Nexus Dx, Inc. by Sinocare, Nova Biomedical, PTS Diagnostics by Danaher Corporation, Quidel Corporation, Radiometer Medical ApS, Randox Laboratories Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trividia Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Cardiac Point of Care Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Analyzers, Kits & Assays, and Software & Services.
  • Based on Biomarker Type, market is studied across Cardiac Troponins, CK-MB Fraction, D-Dimer, Heart-Type Fatty Acid-Binding Protein (H-FABP), Homocysteine, hs C-reactive Protein (CRP), Ischemia-Modified Albumin (IMA), Myoglobin, Natriuretic Peptides (NPs), and sCD40L. The Natriuretic Peptides (NPs) is further studied across Atrial Natriuretic Peptide (ANP), B-type Natriuretic Peptide (BNP), and N-terminal proBNP (NT-proBNP).
  • Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of cardiovascular disorders among the population
      • 5.1.1.2. Favorable government initiatives for the introduction of POC testing
      • 5.1.1.3. Improving healthcare expenditure across economies worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Fluctuating cost of materials and components used in cardiac POC testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements and continuous advancements in cardiac POC testing
      • 5.1.3.2. Advances in the development of new biomarkers to improve testing capabilities
    • 5.1.4. Challenges
      • 5.1.4.1. Operational and technical complexities in cardiac POC testing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing demand for multiplex assays across clinics
    • 5.2.2. Biomarker Type: Increasing demand for heart-type fatty acid-binding protein (H-FABP) and ischemia-modified albumin (IMA) for early cardiac detection
    • 5.2.3. End-user: Rising usage of cardiac POC testing in diagnostic laboratories for complex systems with high sample capacities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cardiac Point of Care Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Analyzers
  • 6.3. Kits & Assays
  • 6.4. Software & Services

7. Cardiac Point of Care Testing Market, by Biomarker Type

  • 7.1. Introduction
  • 7.2. Cardiac Troponins
  • 7.3. CK-MB Fraction
  • 7.4. D-Dimer
  • 7.5. Heart-Type Fatty Acid-Binding Protein (H-FABP)
  • 7.6. Homocysteine
  • 7.7. hs C-reactive Protein (CRP)
  • 7.8. Ischemia-Modified Albumin (IMA)
  • 7.9. Myoglobin
  • 7.10. Natriuretic Peptides (NPs)
    • 7.10.1. Atrial Natriuretic Peptide (ANP)
    • 7.10.2. B-type Natriuretic Peptide (BNP)
    • 7.10.3. N-terminal proBNP (NT-proBNP)
  • 7.11. sCD40L

8. Cardiac Point of Care Testing Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals & Clinics
  • 8.4. Research & Academic Institutes

9. Americas Cardiac Point of Care Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cardiac Point of Care Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cardiac Point of Care Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Hipro Point-of-Care Diagnostics Launched in India
    • 12.3.2. Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease
    • 12.3.3. Cipla expands diagnostics portfolio, launches point-of-care testing device
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abaxis, Inc. by Zoetis Inc
  • 2. Abbott Laboratories
  • 3. ACON Laboratories, Inc.
  • 4. Beckman Coulter
  • 5. Becton, Dickinson and Company
  • 6. Bio-Rad Laboratories, Inc.
  • 7. bioMerieux SA
  • 8. Cardiac Insight Inc.
  • 9. CardioGenics Holdings Inc.
  • 10. Chembio Diagnostic Systems, Inc. by Biosynex
  • 11. EKF Diagnostics
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Fujirebio
  • 14. Horiba, Ltd.
  • 15. I-Sens Inc.
  • 16. LifeSign LLC
  • 17. Nexus Dx, Inc. by Sinocare
  • 18. Nova Biomedical
  • 19. PTS Diagnostics by Danaher Corporation
  • 20. Quidel Corporation
  • 21. Radiometer Medical ApS
  • 22. Randox Laboratories Ltd.
  • 23. Siemens Healthineers AG
  • 24. Thermo Fisher Scientific Inc.
  • 25. Trividia Health, Inc.

LIST OF FIGURES

  • FIGURE 1. CARDIAC POINT OF CARE TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIAC POINT OF CARE TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CARDIAC POINT OF CARE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CARDIAC POINT OF CARE TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CARDIAC TROPONINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK-MB FRACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY D-DIMER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART-TYPE FATTY ACID-BINDING PROTEIN (H-FABP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOMOCYSTEINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HS C-REACTIVE PROTEIN (CRP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ISCHEMIA-MODIFIED ALBUMIN (IMA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ATRIAL NATRIURETIC PEPTIDE (ANP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE (BNP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY N-TERMINAL PROBNP (NT-PROBNP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SCD40L, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 68. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 72. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 141. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 157. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 161. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 199. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2023